ArticleCurrent issues in molecular biology2026
Laennec Attenuates Alcohol-Induced Hepatic Steatosis and Oxidative Stress in a Murine Model.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcoholic liver disease (ALD) represents a major global health burden, encompassing a spectrum of hepatic abnormalities ranging from steatosis to cirrhosis and hepatocellular carcinoma. Laennec, a human placenta-derived hydrolysate, was evaluated for its therapeutic effects on alcohol-induced fatty liver in an experimental animal model.
methodsAnimals were pretreated with alcohol for 2 weeks, followed by the co-administration of alcohol and Laennec for 4 weeks. The study included four groups: normal control, alcohol-only, and low- and high-dose Laennec-treated groups.
resultsAlcohol administration significantly elevated the serum ALT levels (3.17-fold vs. control), indicating hepatocellular injury, whereas Laennec treatment reduced the ALT levels in a dose-dependent manner. The AST levels increased in the alcohol-only group, although the change was not statistically significant; however, the AST levels decreased in the low-dose Laennec-treated groups. The AST/ALT ratio showed significantly dose-dependent recovery in the high-dose group. Laennec treatment attenuated hepatic lipid accumulation and inflammation, with the most pronounced effects observed in the high-dose group. Regarding alcohol-metabolizing enzymes, Laennec exhibited an inhibitory effect on alcohol-induced ADH activity, with no significant effect on ALDH. CYP2E1 activity was suppressed in a dose-dependent manner following Laennec administration. No significant changes were observed in the GPx activity. Additionally, high-dose Laennec significantly restored the catalase and STAT3 (Ser727) phosphorylation levels. Histopathological analysis (H&E staining) demonstrated marked reductions in lipid droplet accumulation and inflammatory cell infiltration in Laennec-treated groups compared to the alcohol-only group.
conclusionThese findings suggest that Laennec exerts hepatoprotective effects against alcohol-induced liver injury and steatosis, as evidenced by improvements in biochemical markers, enzyme activity, and histological features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.